Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (265)	9/12/2002 11:06:18 PM
From: aknahow	Read Replies (1) \| Respond to of 631

Rick, do you mean BGEN made a prior reply to the FDA's request for a complete response? I did think the FDA was obligated to respond in six months, just not obligated to approve the drug. " Putting all of the BS aside..... this is a resubmission, addressing major deficiencies. Moreover, the response OBJECTIVE is within six months, but FDA is not obligated to meet it."